Patient Education

AbstractLight chain amyloidosis and transthyretin amyloidosis are rare protein misfolding disorders characterized by amyloid deposition in organs, varied clinical…

Cardiac amyloidosis (CA) is a progressive condition resulting from the deposition of misfolded proteins in the heart as amyloid fibrils, leading to structural and…

BACKGROUNDTransthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a fatal disease, caused by misfolded transthyretin depositing as amyloid fibrils in the heart.…

This study aimed to increase the index of suspicion for transthyretin amyloidosis (ATTR) among cardiologists leading to increased screening for amyloidosis.MethodsA…

Cardiac amyloidosis is becoming increasingly recognized as an etiology for heart failure (HF). Most cases of amyloid cardiomyopathy will fall into one of two…

MedStar Health was the first and among the most prominent U.S. enrollers of participants in this important global Phase III clinical trial of a new drug to treat…

Patients praised the revolutionary work of the National Amyloidosis Centre (NAC) at the Royal Free Hospital ahead of World Amyloidosis Day last week. The NAC…

Patients undergoing trigger release surgery are known to be at increased risk of amyloidosis and heart failure, and therefore, amyloidosis screening during trigger…

IntroductionLight chain (AL) amyloidosis is a rare and complex disease which can affect various systems of the body. In common with many rare and multisystemic…

If you’re one of the millions of Americans who suffer from carpal tunnel syndrome (CTS), you may want to speak to your doctor about your heart health. A new study…